InflaRx Receives Nasdaq Deficiency Notice Over Minimum Bid Price

Got story updates? Submit your updates here. ›

InflaRx N.V., a biopharmaceutical company focused on anti-inflammatory therapeutics, announced that it has received a notice from Nasdaq indicating that its stock price has closed below the minimum $1 per share requirement for continued listing on the exchange. The company has been provided an initial period of 180 calendar days, or until September 7, 2026, to regain compliance.

Why it matters

Maintaining Nasdaq listing is critical for InflaRx to access public capital markets and continue funding its drug development programs. The company will need to take steps to boost its stock price above the $1 threshold to avoid potential delisting, which could significantly impact the business.

The details

According to the notice, InflaRx's ordinary shares have closed below the $1 minimum bid price for the last 30 consecutive business days, triggering the deficiency. The company can regain compliance by having a closing bid price of at least $1 per share for a minimum of 10 consecutive business days. If InflaRx is unable to do so within the initial 180-day period, it may be eligible for an additional 180-day grace period by transferring to the Nasdaq Capital Market, provided it meets other listing requirements.

• InflaRx received the Nasdaq deficiency notice on March 11, 2026.
• The company has until September 7, 2026 to regain compliance with the $1 minimum bid price.

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.